In clinical practice, the expression or the absence of these elements allows us to distinguish between different cancer subtypes (Luminal A, Luminal B, HER2 positive and Triple negative breast cancers), which require different therapeutic approaches [3]. This evidence concerns the gene ERBB2 and breast cancer.